Drug intelligence / Profile preview

stylissa carteri primmorph extract

Development stage: Preclinical
Modality: Small Molecules
Administration: Parenteral

Overview

Stylissa carteri primmorph extract is a natural product preparation derived from the 3D cell culture (primmorphs) of the marine sponge *Stylissa carteri*. Research indicates that this extract possesses antiproliferative properties, specifically inducing cell cycle arrest in HepG2 (hepatocellular carcinoma) cells. The use of primmorph culture systems is designed to provide a sustainable and controlled method for producing bioactive marine metabolites, overcoming the supply challenges associated with harvesting wild sponges. While the mesohyl of *S. carteri* lacks significant anticancer activity, the primmorph-derived extract shows potential as a source for novel chemotherapeutic agents.

Other names: Stylissa carteri primmorph extracts. carteri primmorph extract

Beyond the preview

Go deeper on stylissa carteri primmorph extract.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on stylissa carteri primmorph extract.

Explore the full profile